These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19997962)

  • 1. ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
    Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
    Invest New Drugs; 2011 Jun; 29(3):506-13. PubMed ID: 19997962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
    Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
    Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines.
    Eicher C; Dewerth A; Ellerkamp V; Fuchs J; Schott S; Armeanu-Ebinger S
    Pediatr Surg Int; 2013 Feb; 29(2):121-7. PubMed ID: 23187893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
    Schott H; Schott S; Schwendener RA
    Bioorg Med Chem; 2009 Oct; 17(19):6824-31. PubMed ID: 19744858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
    Weinreich J; Schott S; Königsrainer I; Zieker D; Königsrainer A; Schott H
    Invest New Drugs; 2011 Dec; 29(6):1294-302. PubMed ID: 20596746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro.
    Weinreich J; Struller F; Sautkin I; Giuashvili S; Reymond M; Königsrainer A; Schott TC
    Invest New Drugs; 2019 Jun; 37(3):415-423. PubMed ID: 30019100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis in cervical cancer cells by the duplex drug 5-FdU-ECyd, coupling 2'-deoxy-5-fluorouridine and 3'-C-ethinylcytidine.
    Schott S; Brüning A
    Gynecol Oncol; 2014 Nov; 135(2):342-8. PubMed ID: 25178996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells
    Schott S; Wimberger P; Klink B; Grützmann K; Puppe J; Wauer US; Klotz DM; Schröck E; Kuhlmann JD
    Oncotarget; 2017 Sep; 8(44):76935-76948. PubMed ID: 29100359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of gastric adenocarcinoma and normal cell lines against combined or conjugated antimetabolites.
    Weinreich J; Struller F; Küper M; Hack A; Königsrainer A; Schott TC
    Anticancer Drugs; 2013 Apr; 24(4):375-83. PubMed ID: 23358120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity and antileukaemic activity of new duplexes linking 3-C-ethynylcytidine and 5-fluorodeoxyuridine.
    Novotny L; Rauko P; Schott H
    Anticancer Res; 2010 Dec; 30(12):4891-8. PubMed ID: 21187467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
    Hrdlicka PJ; Jepsen JS; Nielsen C; Wengel J
    Bioorg Med Chem; 2005 Feb; 13(4):1249-60. PubMed ID: 15670934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer molecular mechanism of 3'-ethynylcytidine (ECyd).
    Wataya Y; Futagami M; Naito T; Uchikubo Y; Yokogawa T; Takenaka K; Kim HS; Matsuda A; Fukushima M; Kitade Y
    Nucleic Acids Res Suppl; 2001; (1):233-4. PubMed ID: 12836350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.
    Fukushima H; Abe T; Sakamoto K; Tsujimoto H; Mizuarai S; Oie S
    BMC Cancer; 2014 Aug; 14():562. PubMed ID: 25087851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECyd).
    Hrdlicka PJ; Jepsen JS; Wengel J
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):397-400. PubMed ID: 16247958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
    Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
    J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antisense oligonucleotides with antitumor activity].
    Otvös L; Sági G
    Magy Onkol; 2004; 48(3):221-7. PubMed ID: 15520872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
    Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
    Invest New Drugs; 2012 Aug; 30(4):1750-5. PubMed ID: 21604021
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
    Ludwig PS; Schwendener RA; Schott H
    Eur J Med Chem; 2005 May; 40(5):494-504. PubMed ID: 15893023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
    Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
    Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil.
    Takatori S; Kanda H; Takenaka K; Wataya Y; Matsuda A; Fukushima M; Shimamoto Y; Tanaka M; Sasaki T
    Cancer Chemother Pharmacol; 1999; 44(2):97-104. PubMed ID: 10412942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.